Three-vessel Coronary Artery Disease Complicated with Congestive Heart Failure in a Highly Aged Patient with Tetralogy of Fallot Having Undergone Palliative Surgeries
Sahara M, Takahashi T, Morita T, Yao A, Nagashima Y, Hirata Y, Nagai R. Three-vessel Coronary Artery Disease Complicated with Congestive Heart Failure in a Highly Aged Patient with Tetralogy of Fallot Having Undergone Palliative Surgeries. Internal Medicine 2006, 45: 1147. PMID: 17106159, DOI: 10.2169/internalmedicine.45.1715.Peer-Reviewed Case Reports and Technical NotesConceptsConcomitant severe coronary artery diseaseTetralogy of FallotCAD risk factorsCongestive heart failureHeart failureRisk factorsUncorrected TOFSevere coronary artery diseaseSuccessful percutaneous coronary interventionPercutaneous coronary interventionCoronary artery diseaseNumber of patientsLong-term survivalAcute exacerbationDisease ComplicatedPalliative surgeryCoronary interventionRare complicationArtery diseaseAged patientsClinical presentationClinical conditionsOlder ageEarly detectionFallotNew Insights in the Treatment Strategy for Pulmonary Arterial Hypertension
Sahara M, Takahashi T, Imai Y, Nakajima T, Yao A, Morita T, Hirata Y, Nagai R. New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension. Cardiovascular Drugs And Therapy 2006, 20: 377-386. PMID: 17124557, DOI: 10.1007/s10557-006-0498-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnticoagulantsAntihypertensive AgentsCalcium Channel BlockersDiureticsDrug Therapy, CombinationHumansHypertension, PulmonaryMaleMiddle AgedNicorandilNitric Oxide DonorsOxygen Inhalation TherapyPhosphodiesterase InhibitorsPiperazinesPurinesPyridazinesSildenafil CitrateSulfonesVasodilator AgentsConceptsPulmonary arterial hypertensionFunctional class IVArterial hypertensionNew York Heart Association functional class IVNYHA functional class IVPhosphodiesterase type 5 inhibitorsClass IVIntravenous prostacyclin therapyOral combination therapyRational pharmacological therapyFirst-line therapyPhosphodiesterase type 3 inhibitorPrimary pulmonary hypertensionEndothelin receptor antagonistsCurrent treatment optionsCalcium channel blockersLong-term efficacyType 5 inhibitorsNovel therapeutic approachesLong-term survivalProstacyclin therapyExercise tolerancePulmonary hypertensionMale patientsPharmacological therapy